These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12494060)

  • 21. [Dosage equivalents of AT1-receptor antagonists available in Germany].
    Dominiak P; Häuser W
    Dtsch Med Wochenschr; 2003 Oct; 128(44):2315-8. PubMed ID: 14593575
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
    Schneider MP; Klingbeil AU; Delles C; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
    Hypertension; 2004 Jul; 44(1):61-6. PubMed ID: 15184349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Losartan vs atenolol in prevention of stroke and cardiovascular disease.
    Fournier A; Oprisiu R; Andrejak M; Fernandez L; Achard JM
    JAMA; 2003 Feb; 289(6):700; author reply 701. PubMed ID: 12585946
    [No Abstract]   [Full Text] [Related]  

  • 24. Losartan vs atenolol in prevention of stroke and cardiovascular disease.
    Messerli FH; Grossman E; Fournier A
    JAMA; 2003 Feb; 289(6):700-1; author reply 701. PubMed ID: 12585945
    [No Abstract]   [Full Text] [Related]  

  • 25. Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
    Schiffrin EL
    Can J Cardiol; 2002 May; 18 Suppl A():15A-18A. PubMed ID: 12045789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist].
    Kjeldsen SE; Omvik P
    Tidsskr Nor Laegeforen; 1996 Feb; 116(4):504-7. PubMed ID: 8644056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
    MMW Fortschr Med; 2003 Nov; 145(45):51. PubMed ID: 14712789
    [No Abstract]   [Full Text] [Related]  

  • 28. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Plus point -- risk reduction].
    MMW Fortschr Med; 2006 Aug; 148(33-34):56-7. PubMed ID: 16981392
    [No Abstract]   [Full Text] [Related]  

  • 30. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
    Hallberg P; Karlsson J; Kurland L; Lind L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
    J Hypertens; 2002 Oct; 20(10):2089-93. PubMed ID: 12359989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implications of the LIFE trial.
    Nadar S; Lim HS; Lip GY
    Expert Opin Investig Drugs; 2003 May; 12(5):871-7. PubMed ID: 12720497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
    Kizer JR; Dahlöf B; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Wachtell K; Edelman JM; Snapinn SM; Harris KE; Devereux RB
    Hypertension; 2005 Jan; 45(1):46-52. PubMed ID: 15583076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta blockers & left ventricular hypertrophy regression.
    George T; Ajit MS; Abraham G
    Indian Heart J; 2010; 62(2):139-42. PubMed ID: 21180305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; López B; Edner M; González A; Díez J; Malmqvist K
    J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What your blood pressure isn't revealing.
    Johns Hopkins Med Lett Health After 50; 2010 Nov; 22(9):4-5. PubMed ID: 21066836
    [No Abstract]   [Full Text] [Related]  

  • 36. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
    Ibsen H; Lindholm LH; Pedersen OL; Dahlöf B; Kjeldsen S
    Ugeskr Laeger; 2003 Jan; 165(5):459-62. PubMed ID: 12599844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Fuchs FD
    Lancet; 2002 Jun; 359(9324):2203; author reply 2203-4. PubMed ID: 12091010
    [No Abstract]   [Full Text] [Related]  

  • 38. [Hypertension in the elderly].
    Ogihara T
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():394-8. PubMed ID: 15171406
    [No Abstract]   [Full Text] [Related]  

  • 39. [What are the consequences of the LIFE Study for general practice].
    Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):48. PubMed ID: 12395704
    [No Abstract]   [Full Text] [Related]  

  • 40. [German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
    Dominiak P; Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):47. PubMed ID: 12395703
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.